- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00999024
Reflectometric Measurement of Retinal Oxygen Saturation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Grade IV and Healthy Subjects
Reflectometric Measurement of Retinal Oxygen Saturation in Patients With COPD Grade IV and Healthy Subjects
An adequate oxygenation and retinal perfusion is essential for the function of the inner retina. There is a wide range of autoregulation mechanisms to ensure a sufficient ocular blood and oxygen supply during changes in systemic blood pressure or intraocular pressure (IOP). Nonetheless, various retinopathies such as diabetic retinopathy, which is the leading cause of blindness in people aged 20-65 in the western world, are highly associated with hypoxia (Pemp and Schmetterer 2008). Hence, measurements of oxygen levels in retinal vessels are needed to further our understanding of these ischemic diseases. It is a well known fact and a commonly employed method to measure oxygen saturation of blood through light transmission (Kramer 1934). However, this approach is not feasible in the human eye. Therefore, reflection must be used, meaning the amount of incident light must be estimated based on the amount of light reflected (for a review see Harris 2003). This is a difficult task and investigators in this field have encountered several problems, including optical complexities, nonlinear sensors and eye movement (Beach et al 1999; Delori 1988). Nonetheless considerable progress has been made over the past decades and the development of an reliable oximeter reported (Hardarson et al 2006).
In the present study this technique will be applied in healthy subjects as well as in patients with COPD during room-air conditions. The procedure takes approximately 15 minutes in each subject and will be performed in only one eye.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology, Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion criteria for healthy subjects:
- Men and women aged between 18 and 99 years
- Tiffeneau Index > 70 %
- Body mass index between 15th and 85th percentile
- Normal ophthalmic findings, ametropia < 3 Dpt.
Inclusion criteria for COPD patients:
- Men and women aged between 18 and 99 years
- COPD grade IV, oxygen dependent and with a forced expiratory volume in 1 second (FEV1) < 30 %
- Body mass index between 15th and 85th percentile
- Normal ophthalmic findings, ametropia < 3 Dpt.
Exclusion Criteria:
Healthy subjects:
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug except oral contraceptives
- Symptoms of a clinically relevant illness in the 3 weeks before the study day
- Blood donation during the previous 3 weeks
COPD patients:
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Health status which does interfere with study procedure or their safety
- Blood donation during the previous 3 weeks
- Symptoms of a clinically relevant illness other than COPD or COPD related in the 3 weeks before the study day
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Healthy subjects
20 healthy subjects will be included
|
COPD Patients
20 Patients with Grade IV COPD will be included
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood oxygen saturation measured in retinal vessel
Time Frame: 15 minutes measured with the RVA
|
15 minutes measured with the RVA
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Systemic blood pressure
Time Frame: 5 minutes
|
5 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerhard Garhofer, MD, Priv.Doz., Medical University of Vienna
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- OPHT - 090709
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Artery
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCentral Retinal Artery OcclusionFrance
-
Xinhua Hospital, Shanghai Jiao Tong University...RecruitingSafety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery OcclusionCentral Retinal Artery OcclusionChina
-
Asociación para Evitar la Ceguera en MéxicoUnknownCentral Retinal Artery OcclusionMexico
-
Oslo University HospitalRecruitingCentral Retinal Artery OcclusionDenmark, Norway, Belgium, Sweden, Finland, Ireland, Lithuania, Australia, Austria
-
Nantes University HospitalCompleted
-
Dar El Oyoun HospitalCairo UniversityCompletedRetinal Artery MacroaneurysmEgypt
-
Kyoto Drug Discovery and Development Co., Ltd.RecruitingCentral Retinal Artery OcclusionUnited States
-
University Hospital TuebingenRecruitingCentral Retinal Artery OcclusionGermany
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedVisual Field | Central Retinal Artery Occlusion | Intra-arterial ThrombolysisChina